🔴 Corcept Therapeutics is trading 4.42% down as U.S. indexes and biotech shares sell off

Corcept Therapeutics is trading at $75.72, down -4.42%, amid a sharp November 5 sell-off across major U.S. indexes and biotech shares.

• The company beat third-quarter estimates but reiterated its $1.1–$1.2 billion 2026 revenue outlook rather than raising it, a factor reported as weighing on shares after the November 3 results.
• That guidance reaction began after the November 3 results; the broad market decline is the clearest explanation for the current move.